Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs)
Here, we developed a new synthetic lethal strategy for further optimizing the eradication of cancer stem cells (CSCs). Briefly, we show that chronic treatment with the FDA-approved antibiotic Doxycycline effectively reduces cellular respiration, by targeting mitochondrial protein translation. The ex...
Saved in:
| Published in: | Oncotarget Vol. 8; no. 40; p. 67269 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
15.09.2017
|
| Subjects: | |
| ISSN: | 1949-2553, 1949-2553 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Here, we developed a new synthetic lethal strategy for further optimizing the eradication of cancer stem cells (CSCs). Briefly, we show that chronic treatment with the FDA-approved antibiotic Doxycycline effectively reduces cellular respiration, by targeting mitochondrial protein translation. The expression of four mitochondrial DNA encoded proteins (MT-ND3, MT-CO2, MT-ATP6 and MT-ATP8) is suppressed, by up to 35-fold. This high selection pressure metabolically synchronizes the surviving cancer cell sub-population towards a predominantly glycolytic phenotype, resulting in metabolic inflexibility. We directly validated this Doxycycline-induced glycolytic phenotype, by using metabolic flux analysis and label-free unbiased proteomics. Next, we identified two natural products (Vitamin C and Berberine) and six clinically-approved drugs, for metabolically targeting the Doxycycline-resistant CSC population (Atovaquone, Irinotecan, Sorafenib, Niclosamide, Chloroquine, and Stiripentol). This new combination strategy allows for the more efficacious eradication of CSCs with Doxycycline, and provides a simple pragmatic solution to the possible development of Doxycycline-resistance in cancer cells. In summary, we propose the combined use of i) Doxycycline (Hit-1: targeting mitochondria) and ii) Vitamin C (Hit-2: targeting glycolysis), which represents a new synthetic-lethal metabolic strategy for eradicating CSCs. This type of metabolic Achilles' heel will allow us and others to more effectively "starve" the CSC population. |
|---|---|
| AbstractList | Here, we developed a new synthetic lethal strategy for further optimizing the eradication of cancer stem cells (CSCs). Briefly, we show that chronic treatment with the FDA-approved antibiotic Doxycycline effectively reduces cellular respiration, by targeting mitochondrial protein translation. The expression of four mitochondrial DNA encoded proteins (MT-ND3, MT-CO2, MT-ATP6 and MT-ATP8) is suppressed, by up to 35-fold. This high selection pressure metabolically synchronizes the surviving cancer cell sub-population towards a predominantly glycolytic phenotype, resulting in metabolic inflexibility. We directly validated this Doxycycline-induced glycolytic phenotype, by using metabolic flux analysis and label-free unbiased proteomics. Next, we identified two natural products (Vitamin C and Berberine) and six clinically-approved drugs, for metabolically targeting the Doxycycline-resistant CSC population (Atovaquone, Irinotecan, Sorafenib, Niclosamide, Chloroquine, and Stiripentol). This new combination strategy allows for the more efficacious eradication of CSCs with Doxycycline, and provides a simple pragmatic solution to the possible development of Doxycycline-resistance in cancer cells. In summary, we propose the combined use of i) Doxycycline (Hit-1: targeting mitochondria) and ii) Vitamin C (Hit-2: targeting glycolysis), which represents a new synthetic-lethal metabolic strategy for eradicating CSCs. This type of metabolic Achilles' heel will allow us and others to more effectively "starve" the CSC population. Here, we developed a new synthetic lethal strategy for further optimizing the eradication of cancer stem cells (CSCs). Briefly, we show that chronic treatment with the FDA-approved antibiotic Doxycycline effectively reduces cellular respiration, by targeting mitochondrial protein translation. The expression of four mitochondrial DNA encoded proteins (MT-ND3, MT-CO2, MT-ATP6 and MT-ATP8) is suppressed, by up to 35-fold. This high selection pressure metabolically synchronizes the surviving cancer cell sub-population towards a predominantly glycolytic phenotype, resulting in metabolic inflexibility. We directly validated this Doxycycline-induced glycolytic phenotype, by using metabolic flux analysis and label-free unbiased proteomics. Next, we identified two natural products (Vitamin C and Berberine) and six clinically-approved drugs, for metabolically targeting the Doxycycline-resistant CSC population (Atovaquone, Irinotecan, Sorafenib, Niclosamide, Chloroquine, and Stiripentol). This new combination strategy allows for the more efficacious eradication of CSCs with Doxycycline, and provides a simple pragmatic solution to the possible development of Doxycycline-resistance in cancer cells. In summary, we propose the combined use of i) Doxycycline (Hit-1: targeting mitochondria) and ii) Vitamin C (Hit-2: targeting glycolysis), which represents a new synthetic-lethal metabolic strategy for eradicating CSCs. This type of metabolic Achilles' heel will allow us and others to more effectively "starve" the CSC population.Here, we developed a new synthetic lethal strategy for further optimizing the eradication of cancer stem cells (CSCs). Briefly, we show that chronic treatment with the FDA-approved antibiotic Doxycycline effectively reduces cellular respiration, by targeting mitochondrial protein translation. The expression of four mitochondrial DNA encoded proteins (MT-ND3, MT-CO2, MT-ATP6 and MT-ATP8) is suppressed, by up to 35-fold. This high selection pressure metabolically synchronizes the surviving cancer cell sub-population towards a predominantly glycolytic phenotype, resulting in metabolic inflexibility. We directly validated this Doxycycline-induced glycolytic phenotype, by using metabolic flux analysis and label-free unbiased proteomics. Next, we identified two natural products (Vitamin C and Berberine) and six clinically-approved drugs, for metabolically targeting the Doxycycline-resistant CSC population (Atovaquone, Irinotecan, Sorafenib, Niclosamide, Chloroquine, and Stiripentol). This new combination strategy allows for the more efficacious eradication of CSCs with Doxycycline, and provides a simple pragmatic solution to the possible development of Doxycycline-resistance in cancer cells. In summary, we propose the combined use of i) Doxycycline (Hit-1: targeting mitochondria) and ii) Vitamin C (Hit-2: targeting glycolysis), which represents a new synthetic-lethal metabolic strategy for eradicating CSCs. This type of metabolic Achilles' heel will allow us and others to more effectively "starve" the CSC population. |
| Author | Lisanti, Michael P Maggiolini, Marcello Bonuccelli, Gloria De Francesco, Ernestina Marianna Sotgia, Federica |
| Author_xml | – sequence: 1 givenname: Ernestina Marianna surname: De Francesco fullname: De Francesco, Ernestina Marianna organization: The Paterson Institute, University of Manchester, Withington, United Kingdom – sequence: 2 givenname: Gloria surname: Bonuccelli fullname: Bonuccelli, Gloria organization: Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC), University of Salford, Greater Manchester, United Kingdom – sequence: 3 givenname: Marcello surname: Maggiolini fullname: Maggiolini, Marcello organization: Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy – sequence: 4 givenname: Federica surname: Sotgia fullname: Sotgia, Federica organization: Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC), University of Salford, Greater Manchester, United Kingdom – sequence: 5 givenname: Michael P surname: Lisanti fullname: Lisanti, Michael P organization: Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC), University of Salford, Greater Manchester, United Kingdom |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28978032$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtPwzAQhC0EoqX0B3BBPpZDILEd2-VWhadUiQOPa-Q4m9bIsUvsSs2B_05Qi8RedjX7aTSaM3TsvAOELrL0OpOckhvvtI-qW0EcBEbkERpnczZPSJ7T43_3CE1D-EyHyZmQZH6KRkTOhUwpGaPvDxNVaxwusHI1vvO7XvfaGge3eIFD7-IaotHYQlwri7VvK-NUNN7h4dOpTY_3GYxb4Raiqrwd8MbCzlTGmtjjwVwrp6HDIUKLNVgb8Kx4LcLVOTpplA0wPewJen-4fyuekuXL43OxWCaa8TwmUupK0bSueFo10LBG5YJrqQgVvGGsShljnFDZ0Bp4zongMuN11khQIssJIxM02_tuOv-1hRDL1oTfIMqB34Zy6ErwjAoqBvTygG6rFupy05lWdX35Vxn5AXlJc1s |
| CitedBy_id | crossref_primary_10_1002_adfm_202422196 crossref_primary_10_1007_s11696_021_01936_w crossref_primary_10_1186_s13058_023_01686_5 crossref_primary_10_1007_s11010_021_04281_4 crossref_primary_10_3389_fmed_2025_1633447 crossref_primary_10_3390_ph14090852 crossref_primary_10_1186_s12935_018_0710_0 crossref_primary_10_1016_j_bbadis_2023_166849 crossref_primary_10_3390_molecules27020358 crossref_primary_10_3390_pr10061222 crossref_primary_10_3390_nu12051501 crossref_primary_10_1016_j_bcp_2022_114966 crossref_primary_10_3389_fonc_2020_01776 crossref_primary_10_3390_cells9071693 crossref_primary_10_1097_MD_0000000000039450 crossref_primary_10_1161_CIRCRESAHA_118_312439 crossref_primary_10_1016_j_semcancer_2020_04_006 crossref_primary_10_1016_j_biopha_2023_114496 crossref_primary_10_3390_molecules25143230 crossref_primary_10_3389_fmicb_2021_643472 crossref_primary_10_4252_wjsc_v12_i11_1295 crossref_primary_10_3390_ijms25168647 crossref_primary_10_3390_ijms26146829 crossref_primary_10_1016_j_ijpharm_2024_124358 crossref_primary_10_3389_fphys_2018_00809 crossref_primary_10_1016_j_canlet_2018_05_039 crossref_primary_10_1007_s12094_024_03553_x crossref_primary_10_3390_medicina58091289 crossref_primary_10_1177_1535370220909309 crossref_primary_10_1016_j_cytogfr_2019_12_002 crossref_primary_10_1002_adma_202202715 crossref_primary_10_23736_S0392_9590_21_04556_9 crossref_primary_10_1042_BCJ20170164 crossref_primary_10_1172_JCI121685 crossref_primary_10_3389_fonc_2021_740720 crossref_primary_10_3389_fonc_2021_689068 crossref_primary_10_3390_cancers14112608 crossref_primary_10_3390_cancers17010059 crossref_primary_10_1039_D5BM00253B crossref_primary_10_3390_antiox10020205 crossref_primary_10_21307_PM_2018_57_4_301 crossref_primary_10_1080_15384101_2018_1515551 crossref_primary_10_1016_j_drup_2025_101226 crossref_primary_10_3389_fonc_2019_00615 crossref_primary_10_3390_cells12232686 crossref_primary_10_3390_molecules25235776 crossref_primary_10_3389_fphar_2019_00681 crossref_primary_10_1186_s13046_021_02134_y crossref_primary_10_3892_ol_2019_10686 crossref_primary_10_3390_cancers16142517 crossref_primary_10_1016_j_freeradbiomed_2022_12_082 crossref_primary_10_1016_j_ejphar_2019_172784 crossref_primary_10_34172_apb_2023_073 crossref_primary_10_1155_2019_7286737 crossref_primary_10_1002_cnr2_1003 crossref_primary_10_1039_D4RA02638A crossref_primary_10_3389_fonc_2018_00452 crossref_primary_10_3390_biom10010079 crossref_primary_10_1002_ejic_201800066 crossref_primary_10_3390_cancers15153775 crossref_primary_10_1186_s12935_020_01719_5 crossref_primary_10_1016_j_ejphar_2021_174593 crossref_primary_10_1016_j_rvsc_2021_02_022 crossref_primary_10_3390_cancers12102780 crossref_primary_10_1016_j_canlet_2020_08_018 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.18632/oncotarget.18428 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 1949-2553 |
| ExternalDocumentID | 28978032 |
| Genre | Journal Article |
| GroupedDBID | --- 53G ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL DIK FRJ GX1 HYE KQ8 M48 NPM OK1 PGMZT RPM 7X8 |
| ID | FETCH-LOGICAL-c465t-88cba30db60bfef4fa576c8a2376f44b04446238f3de656276816d1f8ea715242 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 74 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000410790500040&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1949-2553 |
| IngestDate | Thu Jul 10 22:04:42 EDT 2025 Mon Aug 18 08:05:14 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 40 |
| Keywords | cancer stem-like cells (CSCs) doxycycline vitamin C mitochondrial biogenesis mitochondrial DNA (mt-DNA) |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c465t-88cba30db60bfef4fa576c8a2376f44b04446238f3de656276816d1f8ea715242 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=18428&path%5B%5D=59194 |
| PMID | 28978032 |
| PQID | 1947613737 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1947613737 pubmed_primary_28978032 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-09-15 |
| PublicationDateYYYYMMDD | 2017-09-15 |
| PublicationDate_xml | – month: 09 year: 2017 text: 2017-09-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Oncotarget |
| PublicationTitleAlternate | Oncotarget |
| PublicationYear | 2017 |
| References | 28039467 - Oncotarget. 2017 Feb 7;8(6):9868-9884 27220421 - Breast Cancer Res. 2016 May 24;18(1):55 22033146 - Cell Cycle. 2011 Dec 15;10(24):4208-16 22665270 - J Mammary Gland Biol Neoplasia. 2012 Jun;17(2):111-7 22236876 - Cancer Biol Ther. 2011 Dec 15;12(12):1085-97 26350063 - Sci Rep. 2015 Sep 09;5:13896 20208035 - J Biomol Screen. 2010 Apr;15(4):427-33 27141887 - Nat Rev Clin Oncol. 2017 Jan;14 (1):11-31 21177425 - Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):262-71 25668730 - Nat Rev Clin Oncol. 2015 Apr;12(4):190 27136895 - Oncotarget. 2016 Jun 7;7(23):34084-99 20587011 - Stem Cell Res Ther. 2010 May 20;1(2):13 25325014 - Front Oncol. 2014 Sep 29;4:262 26087310 - Oncotarget. 2015 Jun 20;6(17 ):14777-95 23172368 - Cell Cycle. 2012 Dec 1;11(23):4390-401 24613622 - Eur J Cancer. 2014 May;50(7):1223-31 18450228 - P R Health Sci J. 2008 Mar;27(1):7-19 22234241 - Cell Cycle. 2012 Jan 15;11(2):253-63 25625193 - Oncotarget. 2015 Mar 10;6(7):4569-84 22395432 - Cell Cycle. 2012 Apr 1;11(7):1445-54 25415228 - Oncotarget. 2014 Nov 30;5(22):11029-37 27344270 - Aging (Albany NY). 2016 Aug;8(8):1593-607 19545218 - Expert Opin Biol Ther. 2009 Aug;9(8):1005-16 26087309 - Oncotarget. 2015 Jun 10;6(16):14005-25 22225869 - Cell Metab. 2012 Jan 4;15(1):4-5 19780738 - Aust N Z J Obstet Gynaecol. 2009 Oct;49(5):525-30 23257779 - Cell Cycle. 2013 Jan 1;12 (1):172-82 26224121 - Cancer Res. 2015 Aug 15;75(16):3203-8 23070475 - Cell Cycle. 2012 Nov 15;11(22):4174-80 12914777 - Biochem Biophys Res Commun. 2003 Aug 29;308(3):492-6 26337609 - IUBMB Life. 2015 Sep;67(9):687-93 26421710 - Oncotarget. 2015 Oct 13;6(31):30472-86 25848948 - PLoS One. 2015 Apr 07;10(4):e0120228 28411284 - Oncotarget. 2017 Mar 2;8(12 ):20309-20327 22134189 - Cell Cycle. 2011 Dec 1;10(23):4047-64 28805671 - Nutrients. 2017 Aug 12;9(8):null 20818174 - Cell Cycle. 2010 Sep 1;9(17):3506-14 28223550 - Oncotarget. 2017 Mar 28;8(13):20667-20678 27570483 - Int J Biol Sci. 2016 Jul 22;12(9):1093-103 20171954 - Biochem Biophys Res Commun. 2010 Apr 2;394(2):249-53 26340526 - Cell Stem Cell. 2015 Sep 3;17(3):260-71 22041887 - Cancer Biol Ther. 2011 Nov 15;12(10):924-38 24699023 - J Stem Cells. 2013;8(3-4):135-49 22722266 - Cell Cycle. 2012 Jul 1;11(13):2545-56 23082721 - Cell Cycle. 2012 Nov 1;11(21):3956-63 26541605 - Science. 2015 Dec 11;350(6266):1391-6 25565207 - Cell Metab. 2015 Jan 6;21(1):81-94 16377171 - Curr Opin Genet Dev. 2006 Feb;16(1):60-4 17785204 - Cancer Cell. 2007 Sep;12(3):230-8 23082722 - Cell Cycle. 2012 Nov 1;11(21):3964-71 26421711 - Oncotarget. 2015 Oct 13;6(31):30453-71 7609676 - Med Hypotheses. 1995 Mar;44(3):207-13 15068981 - Ann Intern Med. 2004 Apr 6;140(7):533-7 8517665 - Anticancer Res. 1993 Mar-Apr;13(2):475-80 |
| References_xml | – reference: 26224121 - Cancer Res. 2015 Aug 15;75(16):3203-8 – reference: 23082722 - Cell Cycle. 2012 Nov 1;11(21):3964-71 – reference: 21177425 - Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):262-71 – reference: 22041887 - Cancer Biol Ther. 2011 Nov 15;12(10):924-38 – reference: 26087310 - Oncotarget. 2015 Jun 20;6(17 ):14777-95 – reference: 25625193 - Oncotarget. 2015 Mar 10;6(7):4569-84 – reference: 16377171 - Curr Opin Genet Dev. 2006 Feb;16(1):60-4 – reference: 8517665 - Anticancer Res. 1993 Mar-Apr;13(2):475-80 – reference: 22225869 - Cell Metab. 2012 Jan 4;15(1):4-5 – reference: 18450228 - P R Health Sci J. 2008 Mar;27(1):7-19 – reference: 26421710 - Oncotarget. 2015 Oct 13;6(31):30472-86 – reference: 22236876 - Cancer Biol Ther. 2011 Dec 15;12(12):1085-97 – reference: 7609676 - Med Hypotheses. 1995 Mar;44(3):207-13 – reference: 23082721 - Cell Cycle. 2012 Nov 1;11(21):3956-63 – reference: 24699023 - J Stem Cells. 2013;8(3-4):135-49 – reference: 25668730 - Nat Rev Clin Oncol. 2015 Apr;12(4):190 – reference: 20208035 - J Biomol Screen. 2010 Apr;15(4):427-33 – reference: 20818174 - Cell Cycle. 2010 Sep 1;9(17):3506-14 – reference: 28039467 - Oncotarget. 2017 Feb 7;8(6):9868-9884 – reference: 23172368 - Cell Cycle. 2012 Dec 1;11(23):4390-401 – reference: 26350063 - Sci Rep. 2015 Sep 09;5:13896 – reference: 22395432 - Cell Cycle. 2012 Apr 1;11(7):1445-54 – reference: 26421711 - Oncotarget. 2015 Oct 13;6(31):30453-71 – reference: 27344270 - Aging (Albany NY). 2016 Aug;8(8):1593-607 – reference: 25325014 - Front Oncol. 2014 Sep 29;4:262 – reference: 23257779 - Cell Cycle. 2013 Jan 1;12 (1):172-82 – reference: 27570483 - Int J Biol Sci. 2016 Jul 22;12(9):1093-103 – reference: 28411284 - Oncotarget. 2017 Mar 2;8(12 ):20309-20327 – reference: 20587011 - Stem Cell Res Ther. 2010 May 20;1(2):13 – reference: 27141887 - Nat Rev Clin Oncol. 2017 Jan;14 (1):11-31 – reference: 19545218 - Expert Opin Biol Ther. 2009 Aug;9(8):1005-16 – reference: 27136895 - Oncotarget. 2016 Jun 7;7(23):34084-99 – reference: 27220421 - Breast Cancer Res. 2016 May 24;18(1):55 – reference: 23070475 - Cell Cycle. 2012 Nov 15;11(22):4174-80 – reference: 28223550 - Oncotarget. 2017 Mar 28;8(13):20667-20678 – reference: 22134189 - Cell Cycle. 2011 Dec 1;10(23):4047-64 – reference: 26087309 - Oncotarget. 2015 Jun 10;6(16):14005-25 – reference: 20171954 - Biochem Biophys Res Commun. 2010 Apr 2;394(2):249-53 – reference: 26541605 - Science. 2015 Dec 11;350(6266):1391-6 – reference: 25565207 - Cell Metab. 2015 Jan 6;21(1):81-94 – reference: 22234241 - Cell Cycle. 2012 Jan 15;11(2):253-63 – reference: 28805671 - Nutrients. 2017 Aug 12;9(8):null – reference: 26340526 - Cell Stem Cell. 2015 Sep 3;17(3):260-71 – reference: 22665270 - J Mammary Gland Biol Neoplasia. 2012 Jun;17(2):111-7 – reference: 12914777 - Biochem Biophys Res Commun. 2003 Aug 29;308(3):492-6 – reference: 22722266 - Cell Cycle. 2012 Jul 1;11(13):2545-56 – reference: 17785204 - Cancer Cell. 2007 Sep;12(3):230-8 – reference: 26337609 - IUBMB Life. 2015 Sep;67(9):687-93 – reference: 25415228 - Oncotarget. 2014 Nov 30;5(22):11029-37 – reference: 19780738 - Aust N Z J Obstet Gynaecol. 2009 Oct;49(5):525-30 – reference: 22033146 - Cell Cycle. 2011 Dec 15;10(24):4208-16 – reference: 15068981 - Ann Intern Med. 2004 Apr 6;140(7):533-7 – reference: 24613622 - Eur J Cancer. 2014 May;50(7):1223-31 – reference: 25848948 - PLoS One. 2015 Apr 07;10(4):e0120228 |
| SSID | ssj0000547829 |
| Score | 2.4620805 |
| Snippet | Here, we developed a new synthetic lethal strategy for further optimizing the eradication of cancer stem cells (CSCs). Briefly, we show that chronic treatment... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 67269 |
| Title | Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs) |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28978032 https://www.proquest.com/docview/1947613737 |
| Volume | 8 |
| WOSCitedRecordID | wos000410790500040&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAMrDwEO-XjMQAQ0Rqu7HDglABsVBV4qFulZ-iEk0KKYgM_HfukgATEhJLhshOHN_F933n8x0hh7HmzDGnIm6DjIBvuMiAoUEgJ1RqhPJOVcUmZK-nBoO03zjciias8mtNrBZql1v0kZ8A2QbGzSWXZ5PnCKtG4e5qU0JjlrQ4QBnUajlQ3z6WGJNVVYXKoHcaAXrmzcamSjg7yTH9QRVvDTcEU7-DzMrYXC39d5jLZLGBmfS81osVMuOzVfLxMJrq8SijXaozRy_y99KWeDTSn9JzWpQZgEFoT0GUj9AZXgi0uZIcrY9plbT-EDB3dOynoD9P0DxgTs0qxrak8HCLevRCMUE0xW2Bgh51b7vF8Rq5v7q8615HTfmFyIqkM42Uskbz2JkkNsEHETRwE6s0xtEEIQxmmgPwpAJ3HlAhA-LSTlw7KK8loALB1slclmd-k1AtY2ZSHhLfNsIl3hidxtxp47UO0iZb5OBrNoeg3jg4nfn8tRj-zOcW2ahFMpzUeTiGwBWlijnb_kPvHbLA0CBj8YfOLmkF-Ln9Hpm3b9NR8bJf6Q1ce_2bT1DB0Aw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vitamin+C+and+Doxycycline%3A+A+synthetic+lethal+combination+therapy+targeting+metabolic+flexibility+in+cancer+stem+cells+%28CSCs%29&rft.jtitle=Oncotarget&rft.au=De+Francesco%2C+Ernestina+Marianna&rft.au=Bonuccelli%2C+Gloria&rft.au=Maggiolini%2C+Marcello&rft.au=Sotgia%2C+Federica&rft.date=2017-09-15&rft.eissn=1949-2553&rft.volume=8&rft.issue=40&rft.spage=67269&rft_id=info:doi/10.18632%2Foncotarget.18428&rft_id=info%3Apmid%2F28978032&rft_id=info%3Apmid%2F28978032&rft.externalDocID=28978032 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1949-2553&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1949-2553&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1949-2553&client=summon |